Key Data in Non-Hodgkin Lymphoma From ASH 2022

Michael R. Bishop, MD


January 03, 2023

The key data on non-Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting and Exposition are discussed by Dr Michael Bishop, from the University of Chicago, Illinois.

He begins with the MATRix/IELSG43 trial of consolidation therapy options in patients with primary central nervous system lymphoma. The study demonstrated that high-dose chemotherapy plus autologous stem cell transplantation is the new standard of care.

Dr Bishop then turns to a number of studies of bispecific antibodies, starting with an examination of relapse rates in patients with large B-cell lymphoma who achieve complete remission after treatment with glofitamab. The results were highly encouraging.

The ELM-2 study of odronextamab in diffuse large B-cell lymphoma is next, and this pivotal phase 2 trial demonstrated that odronextamab achieves clinically meaningful results.

Dr Bishop moves on to mosunetuzumab monotherapy in follicular lymphoma, which again showed durable efficacy and manageable safety in a phase 2 trial.

In closing, he reports on a comparison of rituximab and watch and wait in asymptomatic, low tumor burden follicular lymphoma. The study showed that, in this case, active treatment significantly delayed disease progression.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.